J. Marion

发表

Gut microbiota density influences host physiology and is shaped by host and microbial factors

Judy H. Cho, K. Hao, A. Kasarskis, 2018, bioRxiv.

Surveillance in inflammatory bowel disease: chromoendoscopy and digital mucosal enhancement.

J. Marion, S. Naymagon, 2013, Gastrointestinal endoscopy clinics of North America.

How effective is current medical therapy for severe ulcerative and Crohn's colitis? An analytic review of selected trials.

A. Kornbluth, H. Janowitz, J. Marion, 1995, Journal of clinical gastroenterology.

Improving Endoscopic Detection of Dysplasia in Inflammatory Bowel Disease: Where Do We Stand?

R. Ungaro, J. Marion, 2018 .

The SCENIC consensus statement on surveillance and management of dysplasia in inflammatory bowel disease: praise and words of caution.

B. Sands, J. Marion, 2015, Gastroenterology.

Colorectal Cancer in Colitis: A Relic of the Past?

J. Marion, 2015, Inflammatory bowel diseases.

An expensive and empty ritual: the continued use of random biopsy technique for detecting dysplasia in patients with colitis--pro.

J. Marion, 2007, Inflammatory bowel diseases.

Chromoendoscopy in Inflammatory Bowel Disease

S. Itzkowitz, J. Marion, 2006 .

Agreement Between Crohn's Disease Endoscopic Severity Scores Derived from Live, Video-recorded, and Central Readings.

J. Colombel, K. Katsanos, B. Cohen, 2018, Inflammatory bowel diseases.

The Effect on the Fetus of Medications Used to Treat Pregnant Inflammatory Bowel-Disease Patients

C. Bodian, D. Present, E. Scherl, 2004, American Journal of Gastroenterology.

Endoscopic submucosal dissection for colorectal dysplasia in inflammatory bowel disease: a US multicenter study

L. M. Wong Kee Song, H. Aihara, S. Friedland, 2022, Endoscopy international open.

Improved Smoking Cessation Rates in a Pharmacist-Led Program Embedded in an Inflammatory Bowel Disease Specialty Medical Home

M. Dubinsky, B. Sands, L. Keefer, 2021, Journal of pharmacy practice.

The Appendix and IBD: Appendectomy Does Not Protect Against Ulcerative Colitis

C. Bodian, H. Janowitz, J. Marion, 1996, Inflammatory bowel diseases.

Infliximab therapy for Crohn's disease fistulae: Number of infusions required for response and time to relapse

C. Bodian, D. Present, E. Scherl, 2000 .

Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.

J. Korzenik, J. Leighton, D. Ramsey, 2010, Gastroenterology.

The modern medical management of acute, severe ulcerative colitis.

J. Marion, D. Present, 1997, European journal of gastroenterology & hepatology.

CLINICAL—ALIMENTARY TRACT Once-Daily Dosing of Delayed-Release Oral Mesalamine (400-mg Tablet) Is as Effective as Twice-Daily Dosing for Maintenance of Remission of Ulcerative Colitis

J. Korzenik, J. Leighton, D. Ramsey, 2010 .

6-Mercaptopurine Is Effective in Crohn’s Disease Without Concomitant Steroids

D. Present, J. Marion, E. Goldstein, 2004, Inflammatory bowel diseases.

Complete bowel obstruction following initial response to infliximab therapy for crohn's disease: A series of a newly described complication

A. Kornbluth, D. Present, E. Scherl, 2000 .

Intravenous Cyclosporine in Refractory Pyoderma Gangrenosum Complicating Inflammatory Bowel Disease

D. Present, E. Scherl, P. Rubin, 2001, Inflammatory bowel diseases.

Toxicity of 6-mercaptopurine/azathioprine in patients with inflammatory bowel disease.

J. Marion, 1998, Inflammatory bowel diseases.

The Effect of Intravenous Cyclosporine on Rates of Colonic Surgery in Hospitalized Patients With Severe Crohn’s Colitis

A. Kornbluth, D. Present, M. Lazarev, 2012, Journal of clinical gastroenterology.

Chromoendoscopy-Targeted Biopsies Are Superior to Standard Colonoscopic Surveillance for Detecting Dysplasia in Inflammatory Bowel Disease Patients: A Prospective Endoscopic Trial

N. Harpaz, J. Waye, C. Bodian, 2008, The American Journal of Gastroenterology.

Beyond the SCENIC route: updates in chromoendoscopy and dysplasia screening in patients with inflammatory bowel disease.

J. Marion, L. Rabinowitz, Nkhil A Kumta, 2021, Gastrointestinal endoscopy.

Rarity of Fistulas in Crohn's Disease of the Jejunum

D. Sachar, A. Greenstein, J. Marion, 1995, Inflammatory bowel diseases.

Rarity of Fistulas in Crohnʼs Disease of the Jejunum

D. Sachar, A. Greenstein, J. Marion, 1995 .

Is cyclosporine as effective in chronic ul cerative colitis as in severe ulcerative colitis

A. Kornbluth, D. Present, H. Janowitz, 1998 .

Once Daily Dosing of Delayed-Release Oral Mesalamine (400 mg Tablet) is as Effective as Twice Daily Dosing for Maintenance of Remission of Ulcerative Colitis: Results of the QDIEM Study: 1185

J. Korzenik, J. Leighton, D. Ramsey, 2009 .

Chromoendoscopy Is More Effective Than Standard Colonoscopy in Detecting Dysplasia During Long-term Surveillance of Patients With Colitis.

N. Harpaz, J. Waye, C. Bodian, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

DOP069 Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: A randomised control trial

B. Sands, E. Szigethy, Helena L. Chang, 2018 .

Complications of GI Endoscopy

J. Marion, 2014 .

Polypectomy versus proctocolectomy for adenoma patients with long-standing ulcerative colitis.

J. Marion, 2006, Inflammatory bowel diseases.

Mucosal Dysplasia in Ileal Pelvic Pouches After Restorative Proctocolectomy

N. Harpaz, A. Kornbluth, D. Present, 2007, Diseases of the colon and rectum.

Myeloid cell influx into the colonic epithelium is associated with disease severity and non-response to anti-Tumor Necrosis Factor Therapy in patients with Ulcerative Colitis

Shadi Toghi Eshghi, C. Argmann, J. Hackney, 2023, bioRxiv.

Fistula response to methotrexate in Crohn's disease: a case series

D. Present, U. Mahadevan, J. Marion, 2003, Alimentary pharmacology & therapeutics.

Short term infliximab toxicity in crohn's disease

D. Present, E. Scherl, M. Chapman, 2000 .

Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.

J. Korzenik, J. Leighton, D. Ramsey, 2010, Gastroenterology.